KLRB1 and hepatocellular carcinoma: CD161+ CD8+ T cells infiltrating early-relapse hepatocellular carcinomas are reported to be significantly associated with a higher second recurrence rate (108) and glioma patients with higher expression of CD161 have significantly shorter overall survival (109).